PHARMAC is seeking feedback
on a proposal relating to the
funding of the TNF-inhibitor
medicines adalimumab (Humira)
and etanercept (Enbrel), both
used to treat people with various
autoimmune and immunemediated
conditions, and
gabapentin (Neurontin), used to
treat epilepsy & neuropathic pain.
The proposal is designed to create
savings of more than $20 million
over 5 years, PHARMAC said.The above article was sent to subscribers in Pharmacy Daily's issue from 15 Jul 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Jul 15
DEMENTIA Australia has appointed comedian Geraldine Hickey (pictured) as its newest Ambassador, coinciding with the Melbourne Memory Walk & Jog event taking place this Sun.
NEW research from the Monash Addiction Research Centre has highlighted a critical shortfall in the availability of Naloxone, a life-saving medication that reverses opioid overdoses, across community pharmacies in Australia’s most populous states.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.